Q2 2014

Source filing unavailable

Q2 2014 · —

Revenue—

Net Income

-$2.56M

N/M vs Q2 2013

EPS Diluted

-$18.55

N/M vs Q2 2013

Operating Income-$2,508,000—

Operating Cash Flowderived-$2,672,000—

Same quarter

Metric	Q2 2014	Q2 2013
Net Income	-$2.56M	-$1.55M
EPS Diluted	-$18.55	-$13.33

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protara Therapeutics, Inc. · CIK 1359931 · Engraved from SEC EDGAR